Home
About
Overview
Sharing Data
ORCID
Help
History (16)
The bundle "plus": the effect of a multidisciplinary team approach to eradicate central line-associated bloodstream infections.
Yellowish, verrucous lesions on the scalp.
Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides.
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation.
See All 16 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation.
Wang Y, Krieg AM. Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. Int Immunol. 2003 Feb; 15(2):223-31.
View in:
PubMed
subject areas
Animals
B-Lymphocytes
Cell Division
CpG Islands
DNA
Mice
Mice, Inbred C57BL
Muramidase
authors with profiles
Arthur M Krieg MD